Logo video2dn
  • ะกะพั…ั€ะฐะฝะธั‚ัŒ ะฒะธะดะตะพ ั ัŽั‚ัƒะฑะฐ
  • ะšะฐั‚ะตะณะพั€ะธะธ
    • ะœัƒะทั‹ะบะฐ
    • ะšะธะฝะพ ะธ ะะฝะธะผะฐั†ะธั
    • ะะฒั‚ะพะผะพะฑะธะปะธ
    • ะ–ะธะฒะพั‚ะฝั‹ะต
    • ะกะฟะพั€ั‚
    • ะŸัƒั‚ะตัˆะตัั‚ะฒะธั
    • ะ˜ะณั€ั‹
    • ะ›ัŽะดะธ ะธ ะ‘ะปะพะณะธ
    • ะฎะผะพั€
    • ะ ะฐะทะฒะปะตั‡ะตะฝะธั
    • ะะพะฒะพัั‚ะธ ะธ ะŸะพะปะธั‚ะธะบะฐ
    • Howto ะธ ะกั‚ะธะปัŒ
    • Diy ัะฒะพะธะผะธ ั€ัƒะบะฐะผะธ
    • ะžะฑั€ะฐะทะพะฒะฐะฝะธะต
    • ะะฐัƒะบะฐ ะธ ะขะตั…ะฝะพะปะพะณะธะธ
    • ะะตะบะพะผะผะตั€ั‡ะตัะบะธะต ะžั€ะณะฐะฝะธะทะฐั†ะธะธ
  • ะž ัะฐะนั‚ะต

ะกะบะฐั‡ะฐั‚ัŒ ะธะปะธ ัะผะพั‚ั€ะตั‚ัŒ ๐ŸŒ ๐—จ๐—ฆ-๐—–๐—›๐—œ๐—ก๐—” ๐—•๐—œ๐—ข๐—ฃ๐—›๐—”๐—ฅ๐— ๐—” ๐——๐—˜๐—”๐—Ÿ๐—ฆ: ๐—š๐—˜๐—ก๐—จ๐—œ๐—ก๐—˜ ๐—ฅ&๐—— ๐—˜๐—ซ๐—ฃ๐—”๐—ก๐—ฆ๐—œ๐—ข๐—ก ๐—ข๐—ฅ ๐—œ๐—ก๐—ก๐—ข๐—ฉ๐—”๐—ง๐—œ๐—ข๐—ก ๐—ข๐—™๐—™๐—ฆ๐—›๐—ข๐—ฅ๐—œ๐—ก๐—š?

  • AI Biopharma Playbook
  • 2025-04-28
  • 59
๐ŸŒ ๐—จ๐—ฆ-๐—–๐—›๐—œ๐—ก๐—” ๐—•๐—œ๐—ข๐—ฃ๐—›๐—”๐—ฅ๐— ๐—” ๐——๐—˜๐—”๐—Ÿ๐—ฆ: ๐—š๐—˜๐—ก๐—จ๐—œ๐—ก๐—˜ ๐—ฅ&๐—— ๐—˜๐—ซ๐—ฃ๐—”๐—ก๐—ฆ๐—œ๐—ข๐—ก ๐—ข๐—ฅ ๐—œ๐—ก๐—ก๐—ข๐—ฉ๐—”๐—ง๐—œ๐—ข๐—ก ๐—ข๐—™๐—™๐—ฆ๐—›๐—ข๐—ฅ๐—œ๐—ก๐—š?
  • ok logo

ะกะบะฐั‡ะฐั‚ัŒ ๐ŸŒ ๐—จ๐—ฆ-๐—–๐—›๐—œ๐—ก๐—” ๐—•๐—œ๐—ข๐—ฃ๐—›๐—”๐—ฅ๐— ๐—” ๐——๐—˜๐—”๐—Ÿ๐—ฆ: ๐—š๐—˜๐—ก๐—จ๐—œ๐—ก๐—˜ ๐—ฅ&๐—— ๐—˜๐—ซ๐—ฃ๐—”๐—ก๐—ฆ๐—œ๐—ข๐—ก ๐—ข๐—ฅ ๐—œ๐—ก๐—ก๐—ข๐—ฉ๐—”๐—ง๐—œ๐—ข๐—ก ๐—ข๐—™๐—™๐—ฆ๐—›๐—ข๐—ฅ๐—œ๐—ก๐—š? ะฑะตัะฟะปะฐั‚ะฝะพ ะฒ ะบะฐั‡ะตัั‚ะฒะต 4ะบ (2ะบ / 1080p)

ะฃ ะฝะฐั ะฒั‹ ะผะพะถะตั‚ะต ัะบะฐั‡ะฐั‚ัŒ ะฑะตัะฟะปะฐั‚ะฝะพ ๐ŸŒ ๐—จ๐—ฆ-๐—–๐—›๐—œ๐—ก๐—” ๐—•๐—œ๐—ข๐—ฃ๐—›๐—”๐—ฅ๐— ๐—” ๐——๐—˜๐—”๐—Ÿ๐—ฆ: ๐—š๐—˜๐—ก๐—จ๐—œ๐—ก๐—˜ ๐—ฅ&๐—— ๐—˜๐—ซ๐—ฃ๐—”๐—ก๐—ฆ๐—œ๐—ข๐—ก ๐—ข๐—ฅ ๐—œ๐—ก๐—ก๐—ข๐—ฉ๐—”๐—ง๐—œ๐—ข๐—ก ๐—ข๐—™๐—™๐—ฆ๐—›๐—ข๐—ฅ๐—œ๐—ก๐—š? ะธะปะธ ะฟะพัะผะพั‚ั€ะตั‚ัŒ ะฒะธะดะตะพ ั ัŽั‚ัƒะฑะฐ ะฒ ะผะฐะบัะธะผะฐะปัŒะฝะพะผ ะดะพัั‚ัƒะฟะฝะพะผ ะบะฐั‡ะตัั‚ะฒะต.

ะ”ะปั ัะบะฐั‡ะธะฒะฐะฝะธั ะฒั‹ะฑะตั€ะธั‚ะต ะฒะฐั€ะธะฐะฝั‚ ะธะท ั„ะพั€ะผั‹ ะฝะธะถะต:

  • ะ˜ะฝั„ะพั€ะผะฐั†ะธั ะฟะพ ะทะฐะณั€ัƒะทะบะต:

Cะบะฐั‡ะฐั‚ัŒ ะผัƒะทั‹ะบัƒ ๐ŸŒ ๐—จ๐—ฆ-๐—–๐—›๐—œ๐—ก๐—” ๐—•๐—œ๐—ข๐—ฃ๐—›๐—”๐—ฅ๐— ๐—” ๐——๐—˜๐—”๐—Ÿ๐—ฆ: ๐—š๐—˜๐—ก๐—จ๐—œ๐—ก๐—˜ ๐—ฅ&๐—— ๐—˜๐—ซ๐—ฃ๐—”๐—ก๐—ฆ๐—œ๐—ข๐—ก ๐—ข๐—ฅ ๐—œ๐—ก๐—ก๐—ข๐—ฉ๐—”๐—ง๐—œ๐—ข๐—ก ๐—ข๐—™๐—™๐—ฆ๐—›๐—ข๐—ฅ๐—œ๐—ก๐—š? ะฑะตัะฟะปะฐั‚ะฝะพ ะฒ ั„ะพั€ะผะฐั‚ะต MP3:

ะ•ัะปะธ ะธะบะพะฝะบะธ ะทะฐะณั€ัƒะทะบะธ ะฝะต ะพั‚ะพะฑั€ะฐะทะธะปะธััŒ, ะŸะžะ–ะะ›ะฃะ™ะกะขะ, ะะะ–ะœะ˜ะขะ• ะ—ะ”ะ•ะกะฌ ะธะปะธ ะพะฑะฝะพะฒะธั‚ะต ัั‚ั€ะฐะฝะธั†ัƒ
ะ•ัะปะธ ัƒ ะฒะฐั ะฒะพะทะฝะธะบะปะธ ั‚ั€ัƒะดะฝะพัั‚ะธ ั ะทะฐะณั€ัƒะทะบะพะน, ะฟะพะถะฐะปัƒะนัั‚ะฐ, ัะฒัะถะธั‚ะตััŒ ั ะฝะฐะผะธ ะฟะพ ะบะพะฝั‚ะฐะบั‚ะฐะผ, ัƒะบะฐะทะฐะฝะฝั‹ะผ ะฒ ะฝะธะถะฝะตะน ั‡ะฐัั‚ะธ ัั‚ั€ะฐะฝะธั†ั‹.
ะกะฟะฐัะธะฑะพ ะทะฐ ะธัะฟะพะปัŒะทะพะฒะฐะฝะธะต ัะตั€ะฒะธัะฐ video2dn.com

ะžะฟะธัะฐะฝะธะต ะบ ะฒะธะดะตะพ ๐ŸŒ ๐—จ๐—ฆ-๐—–๐—›๐—œ๐—ก๐—” ๐—•๐—œ๐—ข๐—ฃ๐—›๐—”๐—ฅ๐— ๐—” ๐——๐—˜๐—”๐—Ÿ๐—ฆ: ๐—š๐—˜๐—ก๐—จ๐—œ๐—ก๐—˜ ๐—ฅ&๐—— ๐—˜๐—ซ๐—ฃ๐—”๐—ก๐—ฆ๐—œ๐—ข๐—ก ๐—ข๐—ฅ ๐—œ๐—ก๐—ก๐—ข๐—ฉ๐—”๐—ง๐—œ๐—ข๐—ก ๐—ข๐—™๐—™๐—ฆ๐—›๐—ข๐—ฅ๐—œ๐—ก๐—š?

๐Ÿš€ How Will Regulatory Exclusivity Reshape Pharma? ๐Ÿš€

The debate between regulatory exclusivity vs. patent exclusivity is heating upโ€”especially for cell and gene therapies (CGTs). As the industry pivots towards regulatory-driven protections, what does this mean for innovation, pricing, and market competition?

๐Ÿ”น Regulatory Exclusivity offers fixed-term market protection (e.g., 12 years for biologics, 7 years for orphan drugs).
๐Ÿ”น Patent Exclusivity relies on legal protections but often faces litigation battles, delaying competition.

Key Predictions:
๐Ÿ“ˆ R&D Shifts: Pharma will prioritize CGTs & biologics over small molecules to maximize exclusivity.

๐Ÿ’ฐ Pricing Pressures: Extended exclusivity = prolonged high drug prices, impacting affordability.
โš– Market Competition: Predictable entry for biosimilars & CGT alternatives, but manufacturing complexity may delay competitors.

๐Ÿ“œ Regulatory Changes: Governments may reassess exclusivity terms to balance innovation with affordability.

Big Pharma Winners & Challenges:
๐Ÿ† Winners: Novartis, Gilead, BMS, Pfizer, and J&Jโ€”leaders in CGTsโ€”stand to gain billions from extended exclusivity.
โš  Challenges: Biosimilar-focused firms like Amgen & Biogen must adapt to shifting regulatory landscapes.

๐Ÿ’ก Bottom Line: The future of drug exclusivity is changing. CGT-focused innovation will thrive, but balancing exclusivity with patient access remains a critical challenge.

๐Ÿ’ฌ What are your thoughts? Should exclusivity policies evolve to support affordability while sustaining innovation? Letโ€™s discuss it! ๐Ÿ‘‡

#Pharma hashtag#Biotech hashtag#CellTherapy hashtag#GeneTherapy #RegulatoryAffairs #Innovation hashtag#DrugPricing hashtag#Healthcare

ะšะพะผะผะตะฝั‚ะฐั€ะธะธ

ะ˜ะฝั„ะพั€ะผะฐั†ะธั ะฟะพ ะบะพะผะผะตะฝั‚ะฐั€ะธัะผ ะฒ ั€ะฐะทั€ะฐะฑะพั‚ะบะต

ะŸะพั…ะพะถะธะต ะฒะธะดะตะพ

  • ะž ะฝะฐั
  • ะšะพะฝั‚ะฐะบั‚ั‹
  • ะžั‚ะบะฐะท ะพั‚ ะพั‚ะฒะตั‚ัั‚ะฒะตะฝะฝะพัั‚ะธ - Disclaimer
  • ะฃัะปะพะฒะธั ะธัะฟะพะปัŒะทะพะฒะฐะฝะธั ัะฐะนั‚ะฐ - TOS
  • ะŸะพะปะธั‚ะธะบะฐ ะบะพะฝั„ะธะดะตะฝั†ะธะฐะปัŒะฝะพัั‚ะธ

video2dn Copyright ยฉ 2023 - 2025

ะšะพะฝั‚ะฐะบั‚ั‹ ะดะปั ะฟั€ะฐะฒะพะพะฑะปะฐะดะฐั‚ะตะปะตะน [email protected]